2nd Circ. Axes Challenge To Medicare Drug Price Negotiations

In a published opinion Thursday, the Second Circuit turned away Boehringer Ingelheim's constitutional and administrative challenge to the Medicare Drug Price Negotiation Program, finding that the program is voluntary and it...

Already a subscriber? Click here to view full article